Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis

详细信息    查看全文

• 作者：I-Chun Chen^a ; Ching-Hung Lin^a ; I-Shiow Jan^b ; Ann-Lii Cheng^a ; ^c ; ^d ; Yen-Shen Lu^a ; ^c ; ^{yslu@ntu.edu.tw" class="auth_mail" title="E-mail the corresponding author}
• 关键词：bevacizumab ; cisplatin ; etoposide ; leptomeningeal carcinomatosis ; metastatic breast cancer
• 刊名：Journal of the Formosan Medical Association
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：115
• 期：4
• 页码：243-248
• 全文大小：420 K

文摘

Patients with leptomeningeal carcinomatosis (LC) from breast cancer is generally resistant to systemic chemotherapy. Bevacizumab may increase intratumor concentration of the chemotherapeutic agents through vascular normalization, although the overall clinical benefit of bevacizumab for metastatic breast cancer is under debate.

Methods

Successful treatment of two breast cancer patients who developed LC after whole brain irradiation treatment for the brain metastases is reported here. Both patients have refractory disease to taxane and anthracycline, and both of them have disease progression under intrathecal methotrexate treatment for LC.

Results

The two patients received systemic chemotherapy with bevacizumab (7.5 mg/kg infusion on Day 1), cisplatin (80 mg/m² infusion for 24 hours on Day 2), and etoposide (80 mg/m² infusion for 2 hours on Days 2–4) at 21–28 day intervals. Both patients achieved best response of negative cerebral spinal fluid cytology study and dramatic improvement of neurologic deficit after treatment. Their overall survival after development of LC was 8 months and 7.5 months respectively.

Conclusion

Bevacizumab plus etoposide and cisplatin might be a new option for breast cancer patients with LC. Further prospective study is warranted.